Abstract-Thrombomodulin (TM), a thrombin receptor protein found on the endothelial cell surface, contains 6 tandem epidermal growth factor (EGF)-like structures. Recombinant human TM peptide containing these 6 EGF-like domains (rTME1-6) exhibits mitogenic activity in Swiss 3T3 cells. We examined the localization of TM in atherosclerotic lesions and the effects of rTME1-6 on the growth of cultured rat vascular smooth muscle cells (SMCs). Immunohistochemical analysis demonstrated that TM antigen was localized on monocytes, macrophages, and vascular SMCs. In cultured vascular SMCs, rTME1-6 accelerated [ 3 H]thymidine uptake into DNA in a dose-dependent manner up to 3.4 times the control level. This mitogenic activity was abolished by addition of polyclonal anti-human TM antibody. The rTME1-6-induced mitogenesis was enhanced by EGF. However, a neutralizing monoclonal antibody against the EGF receptor (monoclonal antibody 225) did not inhibit the mitogenic activity of rTME1-6. Calphostin C, a specific protein kinase C inhibitor, and lavendustin-A, an inhibitor of EGF receptor-specific protein tyrosine kinase, inhibited the mitogenic activities of both rTME1-6 and EGF. Finally, rTME1-6 treatment increased the level of phosphorylated mitogen-activated protein kinase in SMCs. Together, these results suggest that TM expression in atherosclerotic lesions may be associated with promotion of atherosclerosis through its mitogenic activity in vascular SMCs.
T hrombomodulin (TM) is a high-affinity receptor for thrombin on the endothelial cell surface. 1 By forming a complex with thrombin, TM alters the procoagulant activity of thrombin and acts as a cofactor in thrombin-catalyzed activation of protein C. 1 Activated protein C inactivates coagulation factors Va and VIIIa, resulting in reduced thrombin formation. Thus, the thrombin-TM pathway is 1 of the major physiological antithrombotic mechanisms in endothelial cells, which makes TM an important regulator involved in maintaining the fluidity of circulating blood. TM consists of 5 distinct domains: the NH 2 -terminal domain, epidermal growth factor (EGF)-like domain, serine/threonine-rich region, transmembrane domain, and cytoplasmic tail. 2 The EGF-like domain consists of 6 tandem EGF-like motifs that are homologous to domain III of the human EGF precursor. 3 These EGF-like structures are associated with the cofactor activity of TM during thrombin-dependent protein C activation. 4, 5 Soluble TM fragments containing the EGF-like domain of native cellular TM 6 have been detected in circulating plasma. 7 These TM fragments likely are produced by proteolytic cleavage from cellular TM after endothelial cell damage. 8 EGF is a mitogen that enhances the proliferation of various types of cells. Its mitogenic activity is mediated by EGF receptors located on the cell surface; these receptors also relay the biological signals of EGF-like growth factors. 9 Recently, Hamada et al 10 reported that recombinant TM peptide containing the 6 EGF-like domains (rTME1-6) has mitogenic activity in Swiss 3T3 fibroblast cells. However, this mitogenic activity may be mediated by a binding site other than the EGF receptor. To date, however, no studies have investigated whether TM may also have mitogenic activity in cells of the vascular system.
Proliferation of intimal smooth muscle cells (SMCs) is an important contributor to the progression of atherosclerosis. 11 Vascular SMC proliferation is controlled by various cytokines and growth factors, depending on the location of the cells in the arterial wall. In the current study, we investigated whether TM binds to vascular cells in atherosclerotic lesions and how rTME1-6 affects the growth of cultured vascular SMCs.
Methods

Materials
Human rTME1-6 was prepared as described previously. 10 Human recombinant EGF was purchased from Pepro Teck. Platelet-derived growth factor (PDGF) AB and insulin were purchased from Sigma Chemical Company. Calphostin C 12, 13 was purchased from Wako. Lavendustin-A 13, 14 and tyrphostin AG370 15 were purchased from Biomol Research Laboratories. A neutralizing monoclonal antibody against the EGF receptor (mAb 225) 13, 16 was purchased from Research Biochemicals International.
Preparation of Human and Rabbit Aortas
Human aortas were obtained from 6 autopsied cases (3 cases of lung carcinoma and 1 case each of pancreatic carcinoma, liver cirrhosis, and diabetes mellitus). Patients included 5 males and 1 female and ranged in age from 52 to 72 years. Rabbit aortas were obtained from animals (Clea Japan) fed a 1% cholesterol chow (Oriental Yeast Company Ltd). for 2 months. Atheromatous plaques of human aortas and fatty streaks of rabbit aortas were fixed with 10% formalin and embedded in paraffin for histological and immunohistochemical examination.
Immunohistochemical Analysis of TM Localization
Polyclonal rabbit anti-human TM antibody was prepared as described previously. 7 Sheep anti-rabbit TM antibody was prepared by immunizing a sheep with rabbit TM. 17 Immunohistochemical staining was performed as described by Hsu et al. 18 Before staining, paraffin sections of human and rabbit aortas were digested with 0.1% trypsin and 10 mmol/L PBS for 30 minutes at 37°C. The human and rabbit aorta sections were then incubated with 10 g/mL anti-human TM antibody and 13 g/mL anti-rabbit TM antibody, respectively, for 2 hours. Rabbit and sheep preimmune sera served as negative controls. Antibody-treated sections were washed 3 times in PBS buffer and then incubated for 60 minutes each in biotinylated secondary antibody and avidin-conjugated peroxidase (Vector Laboratories); sections were washed between each step. After the final series of washes, peroxidase was developed using 0.2% diaminobenzidine and 50 mmol/L Tris-HCl, pH 7.6, supplemented with 0.3% hydrogen peroxide to yield a brown reaction product. The reaction was stopped by washing with water, and the tissues were counterstained with hematoxylin.
In human sections, intimal monocytes and macrophages were detected immunohistochemically using the monoclonal mouse antihuman antibody HAM56 (Dako). 19 SMCs were identified using a monoclonal mouse anti-human ␣-SM actin antibody (Sigma).
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Isolation and Culture of Rat Arterial SMCs
Arterial medial SMCs obtained from the thoracic aorta of male Wistar rats (2 to 3 months old) were isolated by the outgrowth of explants as described previously. 21 In brief, specimens were dissected and cut into small pieces. Explants were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FBS, penicillin (100 U/mL), and streptomycin (70 mol/L) at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. Cultured SMCs were used for the following experiments after repeated (5 to 8) passages.
Cell Proliferation
Rat SMCs were subcultured in 6-well plates at a density of 10 4 cells per well and incubated for 24 hours at 37°C. The culture medium was removed, and adherent cells were exposed to 1 nmol/L rTME1-6 in DMEM and 1% FBS. The medium was replaced every 2 days. Cells were harvested every other day using 0.25% trypsin and 0.02% EDTA, and the number of cells was counted with a hemocytometer.
DNA Synthesis
Rat SMCs were subcultured in 24-well microplates and grown almost to confluence to avoid bias from contact inhibition. Cells were then made quiescent by incubation in serum-free DMEM for 48 hours. Quiescent cells were exposed to several concentrations of rTME1-6 peptide and various mitogens for different times at 37°C and labeled with [ 3 H]thymidine (1 Ci/well) for the last 8 hours of incubation. To investigate the mechanism of cell growth regulation, several kinase inhibitors (calphostin C, lavendustin-A, and tyrphostin AG370) were added at concentrations that inhibited their signaling pathways but did not affect the basal growth rate of SMCs. The culture medium was removed, and excess [ 3 H]thymidine was recovered by washing 4 times with ice-cold PBS and precipitating with trichloroacetic acid. Cells were detached with 1N NaOH and collected in a tube. The radioactivity of the collected cells was determined using a liquid scintillation counter (Aloka). The measured radioactivity was correlated with the protein concentration, which was measured by using Lowry's method.
Determination of Mitogen-Activated Protein Kinase Activity in Cell Extracts
Mitogen-activated protein kinase (MAPK) activity in cell extracts was measured using a p42/p44 MAPK kit (Amersham). Growtharrested rat SMCs were stimulated for 10 minutes at 37°C with rTME1-6 peptide or EGF and then lysed in 10 mmol/L Tris, 150 mmol/L NaCl, 2 mmol/L EGTA, 2 mmol/L DTT, 1 mmol/L orthovanadate, 1 mmol/L PMSF, and 1.5 mol/L aprotinin, pH 7.4. The lysate was cleared by centrifugation at 25 000g for 20 minutes at 4°C. MAPK activity was measured by using 10 L of supernatant and 10 L of substrate buffer containing the phosphorylation sequence PLS/TP 22 and HEPES buffer containing Mg 2ϩ , pH 7.4. The reaction was terminated after 30 minutes by adding 50 mol/L [␥-
32 P]ATP (20 Ci/mmol). MAPK catalyzed the transfer of the ␥-phosphate group of ATP to a peptide highly selective for p42/p44 MAPK. The phosphorylated peptide was separated by spotting onto binding paper. After the paper was washed with 75 mmol/L orthophosphoric acid and water, the extent of phosphorylation was determined by liquid scintillation counting.
MAPK Activity Assay by Western Blot Analysis
MAPK activity also was assessed by Western blot analysis using the PhosphoPlus MAPK antibody kit (New England BioLabs). Rat SMCs stimulated for 10 minutes with rTME1-6 peptide or EGF were lysed in 62.5 mmol/L Tris-HCl, pH 6.8, 2% (wt/vol) SDS, 10% glycerol, 50 mmol/L DTT, and 0.1% (wt/vol) bromphenol blue. The lysate was sonicated for 15 seconds, heated at 100°C for 5 minutes, and centrifuged at 8000g for 5 minutes at 4°C. The supernatant was subjected to SDS-polyacrylamide gel electrophoresis, and the resolved proteins were electrophoretically transferred onto nitrocellulose membranes. The blots were probed with a rabbit antiphosphotyrosine MAPK antibody to quantify activated MAPK or with a rabbit phosphorylation-state-independent MAPK antibody as a control. Western blot analysis was performed as described previously using the primary antibodies at 1/1000 dilutions. 23 The immunoreactive proteins were visualized by using enhanced chemiluminescence.
Statistical Analyses
All results are expressed as meanϮSD. Statistical significance was determined with Student's t test and 1-way ANOVA as appropriate. The Stat View statistical program (Abacus Concepts) was used. Values of PϽ0.05 were considered statistically significant.
Results
Localization of TM in Human and Rabbit Atherosclerotic Lesions
The presence of TM was determined immunohistochemically in atherosclerotic lesions of human aortas obtained from autopsied cases as well as in fatty streaks of rabbit aortas obtained from animals fed a 1% cholesterol diet. In the human aortas, TM was detected on monocytes and macro-phages, which were identified using mAb HAM56, and intimal SMCs, which were identified using an antibody against ␣-SM actin ( Figure 1C ). Medial SMCs also expressed TM ( Figure 1D ). In the rabbit aortas, TM expression was demonstrated in foamy macrophages, intima, and endothelial cells ( Figure 1F ). In contrast to what was observed in human aortas, medial SMCs in rabbit aortas expressed little TM. In both human ( Figure 1E ) and rabbit ( Figure 1G ) aortas, the specificity of the anti-TM antibody was demonstrated on endothelial cells at the vasa vasorum in the adventitia. An absorption test was performed to evaluate the specificity of the polyclonal antibody for TM; incubation of the polyclonal antibody with excess TM before immunostaining led to a complete disappearance of the staining reaction.
Effect of rTME1-6 on SMC Growth and DNA Synthesis
To investigate the effects of rTME1-6 on SMC proliferation, the cells were cultured in DMEM and 1% FBS in the presence or absence of 1 nmol/L rTME1-6 for 14 days. rTME1-6 significantly increased SMC proliferation 3.8-fold (Figure 2 ). We also analyzed the effects of rTME1-6 on [
3 H]thymidine uptake into the DNA of rat SMCs. After the cells were made quiescent by incubation in serum-free DMEM, they were incubated with or without 1 nmol/L rTME1-6 for various periods of time. [ 3 H]Thymidine was added for the last 8 hours. Maximal [ 3 H]thymidine incorporation into DNA, which occurred 28 hours after addition of rTME1-6, was about 3.4-fold higher than that of cells cultured in serum-free Immunohistochemical staining of TM in human and rabbit atherosclerotic lesions. Human aortas were obtained from 6 autopsied cases. Serial sections were immunologically stained with HAM56, an mAb specific for monocytes and macrophages (A); anti-␣-SM actin antibody, which is specific for SMCs (B); and anti-human TM antibody (C, D, and E). Monocytes and macrophages in the intima and SMCs in both the intima and media expressed TM (C and D). Atheromatous lesions were obtained from rabbits fed a 1% cholesterol diet. Foamy macrophages immunoreacted with anti-rabbit TM antibody, but medial SMCs showed no TM expression (F). The specificity of the anti-TM antibody is demonstrated on the endothelial cells at the vasa vasorum in adventitia (E, human; G, rabbit). Magnification A, ϫ50; B, ϫ50; C, ϫ66; D, ϫ33; E, ϫ66; F, ϫ66; and G, ϫ66. medium ( Figure 3A) . The dose dependence of rTME1-6-mediated growth stimulation was analyzed by culturing the cells in serum-free medium with increasing rTME1-6 concentrations for 28 hours. These analyses showed that [ 3 H]thymidine incorporation reached a plateau at about 3.5 times the control levels at a concentration of 1 nmol/L rTME1-6 ( Figure 3B ). In contrast, boiled rTME1-6 had no effect on either cell proliferation or [ 3 H]thymidine uptake into the DNA of rat SMCs. 3 H]thymidine uptake into the DNA of rat SMCs even at an EGF concentration of 1.6 nmol/L, which had a maximal effect on uptake (Table 1) . Incubation with a 100-fold molar excess of polyclonal rabbit anti-human TM antibody completely inhibited the rTME1-6-induced increase in [ 3 H]thymidine uptake but had no effect on the increase in uptake induced by EGF or PDGF (Figure 4 ).
Effect of rTME1-6 and Various Growth
Effect of Neutralizing Anti-EGF Receptor Antibody on rTME1-6-Induced Mitogenic Activity
The mitogenic activity of rTME1-6 in Swiss 3T3 cells has been shown to be mediated by binding of the peptide to a specific site different from the EGF receptor. To determine whether this also was true in rat SMCs, we examined the effect of mAb 225 on rTME1-6-induced mitogenic activity in rat SMCs ( Figure 5 ). mAb 225 is directed against the extracellular domain of the human EGF receptor and can inhibit ligand binding of the EGF family to both human and rat EGF receptors. 13, 16 To determine its effects, quiescent cells were exposed to rTME1-6 (1 nmol/L) or EGF (1.6 nmol/L) in the absence or presence of mAb 225 (200 nmol/L) for 28 hours at 37°C. The antibody did not significantly inhibit the rTME1-6-induced increase in [ 3 H]thymidine uptake.
Effects of Calphostin C, Lavendustin-A, and Tyrphostin AG370 on rTME1-6-Induced DNA Synthesis
To investigate the mitogenic signaling pathway underlying the activity of rTME1-6, we analyzed the effects of calphostin C (a protein kinase C inhibitor), lavendustin-A (a protein Figure 2 . Effect of rTME1-6 on proliferation of rat SMCs. Rat SMCs were exposed to DMEM containing 1% FBS with (OE) or without (F) 1 nmol/L rTME1-6. Medium was replaced every 2 days. Cells were counted every other day. Data are meanϮSD of triplicate cultures. Student's t test was used to evaluate differences between the 2 groups at various times. *PϽ0.05, **PϽ0.01. tyrosine kinase inhibitor specific for the EGF receptor), and tyrphostin AG370 (a tyrosine kinase inhibitor specific for the PDGF receptor) on mitogenic activity in SMCs ( Figure 6 ). Quiescent cells were treated with rTME1-6, EGF, PDGF, or insulin in the presence or absence of calphostin 3 H]thymidine uptake induced by rTME1-6 or EGF to 60Ϯ4% and 55Ϯ5%, respectively, of the control value ( Figure 6A ). In contrast, the increase in [ 3 H]thymidine uptake caused by PDGF and insulin was not significantly affected. Lavendustin-A also significantly inhibited the increase in [ 3 H]thymidine uptake caused by rTME1-6 (61Ϯ4% of the control value) and EGF (68Ϯ7% of the control value) but not by PDGF and insulin ( Figure 6B ). Finally, tyrphostin AG370 significantly inhibited the mitogenic activity of PDGF (35Ϯ5% of the control value) but not of rTME1-6 and EGF ( Figure 6C ).
MAPK Activity in Rat SMCs Treated With rTME1-6
To examine whether MAPK was involved in rTME1-6-induced mitogenic activity, MAPK activity was determined by 2 different methods, an enzyme bioassay and immunological detection of activated MAPK. In the enzyme bioassay, MAPK activity is calculated from the extent to which [ 32 P] is transferred from the ␥-phosphate of ATP to a peptide that is highly selective for p42/p44 MAPK. MAPK activity was stimulated by both rTME1-6 (275Ϯ22% of the control value) and EGF (248Ϯ14% of the control value). This effect was concentration dependent (Table 2) .
For immunological analysis, both total and active MAPK were visualized by Western blotting. Immunoblots of the lysates of cells treated with rTME1-6 or EGF and probed with anti-phosphotyrosine MAPK antibody showed higher levels of activated phosphotyrosine MAPK than did control cells. However, the levels of total MAPK in the cell lysates did not differ among rTME1-6-treated, EGF-treated, and control cells (Figure 7 ).
Discussion
TM is widely distributed in the endothelium of human arteries and veins, lymphatic vessels, syncytiotrophoblasts, 24 synovial lining cells, 25 monocytes, 26 platelets, 27 and neutrophils. 28 It acts as a cofactor during thrombin-dependent protein C activation. The anticoagulant activity of TM depends on the local cell-membrane status. 29, 30 TM serves as a regulator in maintaining the fluidity of circulating blood; accordingly, TM downregulation on damaged endothelial cells potentiates the prothrombotic properties of the vascular wall, promotes coagulation, and contributes to thrombosis.
The current study has demonstrated TM antigen expression in atherosclerotic lesions. TM was constantly expressed in monocytes and macrophages in the atherosclerotic lesions of human and rabbit aortas. In human aortas, TM expression also occurred in intimal and medial SMCs. In rabbit aortas, in contrast, no TM expression was detectable in medial SMCs. These differences in TM expression in the vascular SMCs of humans and rabbits may be attributable to species differences.
TM contains several regions that are homologous to EGF. Mature EGF, which is produced by proteolytic cleavage of the extracellular domain of an integral membrane precursor, is present in various body fluids, such as circulating plasma. 31 EGF binds to a specific receptor on the plasma membrane of cells to initiate mitogenic activity. TM possesses EGF-like domains. A recent study found that the rTME1-6 peptide, which includes the EGF-like domains, has mitogenic activity in Swiss 3T3 fibroblasts. 10 In the current study, we expanded this observation by demonstrating that rTME1-6 also has mitogenic activity in cultured vascular SMCs. It appears likely that a specific binding site for rTME1-6 that may be structurally homologous to the EGF receptor and that may be required for the mitogenic activity of the EGF-like TM domain exists. rTME1-6 further increased [ 3 H]thymidine 
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incorporation into the DNA of rat SMCs even at the concentration of EGF that showed a maximal effect on [ 3 H]thymidine uptake. On the other hand, a neutralizing monoclonal anti-EGF receptor antibody inhibited the EGF-induced, but not the rTME1-6-induced, synthesis of DNA. These findings suggest that the binding site that mediates the mitogenic activity of rTME1-6 is not the EGF receptor.
These observations suggest that rTME1-6 binds to a site that differs from the EGF-binding domain. To clarify this explanation, we studied a ligand-binding assay using 125 I-labeled rTME1-6.
125
I-rTME1-6 (32 000 cpm/mg) was prepared by using the lactoperoxidase method. Quiescent rat SMCs were exposed to several concentrations of 125 I-rTME1-6 with and without a 100-fold excess of cold rTME1-6 for 3 hours at 37°C. Specific binding of 125 I-rTME1-6 to cultured SMCs was calculated as the difference between the radioactivity bound in the absence of cold rTME1-6 and that bound in its presence. Scatchard plot analysis of specific binding indicated a single class of binding site (data not shown). *Growth-arrested rat SMCs were exposed to rTME1-6 or EGF. MAP kinase activity in the cell extracts was determined from the extent of phosphorylation of myelin basic protein by p44/p42 MAP kinase.
†MeanϮSD of triplicate cultures. Student's t test was used to evaluate differences.
‡PϽ0.05. §PϽ0.01.
To investigate the signaling pathway that underlies the mitogenic activity of rTME1-6, we analyzed the effects of 3 kinase inhibitors. These include calphostin C, the protein kinase C inhibitor; lavendustin-A, which inhibits a protein tyrosine kinase specific for the EGF receptor; and tyrphostin AG370, a tyrosine kinase inhibitor specific for the PDGF receptor.
Protein kinase C-mediated signaling is 1 of the mitogenic pathways affecting vascular SMCs. Leszczynski et al 12 reported that rat vascular SMCs cease to proliferate and undergo apoptosis when they are exposed to calphostin C. Protein kinase C also may be involved in EGFdependent mitogenic activity by activating phospholipase C and adenyl cyclase. 32, 33 In the current study, treatment with calphostin C significantly reduced the [ 3 H]thymidine uptake induced by rTME1-6 and EGF, suggesting that the mitogenic activity of rTME1-6, as well as the mitogenic activity of EGF, involves protein kinase C activation.
Antiproliferative compounds called tyrphostins 34 specifically inhibit the EGF receptor tyrosine kinase. These compounds also inhibit EGF receptor autophosphorylation and EGF-dependent tyrosine phosphorylation of endogenous substrates, such as phospholipase CII. 35 Moreover, the intracellular effects of tyrphostins are quantitatively correlated with the inhibition of EGF-dependent cell proliferation. 35 One tyrphostin, lavendustin-A, significantly reduces the mitogenic activity of EGF. 13, 14 Similarly, in the current study, lavendustin-A significantly reduced the uptake of [ 3 H]thymidine by SMCs in response to both rTME1-6 and EGF.
Tyrphostin AG370 is a highly potent blocker of PDGFinduced mitogenesis. Bryckaert et al 15 reported that tyrphostin AG370 inhibits PDGF-induced mitogenesis and phosphorylation without affecting receptor-mediated PDGF binding and internalization. We demonstrated in this study that in SMCs, tyrphostin AG370 significantly inhibited PDGF-induced DNA synthesis but had no effect on rTME1-6-or EGF-induced DNA synthesis. Together, these results suggest that protein kinase C signaling and lavendustin-A-sensitive tyrosine kinase signaling are involved in the rTME1-6-induced mitogenic activity on SMCs. Thus, rTME1-6 appears to act through a mechanism similar to that of EGF.
Phosphorylation of cellular protein is important in regulating cell growth and the responses to extracellular stimuli. It is well known that the response to mitogens binding to receptors with intrinsic tyrosine kinase activity involves the activation of MAPKs. In addition, MAPKs are activated by stimuli, such as cytokines; hormones that bind to G protein-coupled receptors; and physical forces, such as fluid shear stress and stretch. 36 Consequently, MAPK appears to serve as a common signaling mechanism for a variety of extracellular stimuli involved in the regulation of cell growth and function. Kusuhara et al 37 showed that oxidized LDL stimulates MAPK activity in cultured vascular SMCs and macrophages. Accordingly, MAPK may play a significant role in the pathways by which oxidized LDL contributes to altered cellular function associated with atherogenesis. Although the effects of rTME1-6 on the MAPK activity of macrophages have not been examined, rTME1-6-mediated stimulation of MAPK in vascular SMCs may contribute to atherogenesis via such a mechanism.
On endothelial cells, TM may serve as an anticoagulant. 1 Oxidized LDL reduces TM transcription in cultured human endothelial cells. The resulting decrease in anticoagulant activity on the cell surface may contribute to the development of atherosclerosis. 38 In monocytic THP-1 cells, however, oxidized LDL has the opposite effect and upregulates TM expression. 39 TM expression in circulating monocytes may play a role in preventing clotting and inflammation, 40 and the oxidized LDL-induced upregulation of TM in monocytes may compensate for TM downregulation in endothelial cells. In the current study, we demonstrated that rTME1-6 also has a mitogenic effect on vascular SMCs, which suggests a role for TM in atherogenesis. Thus, it appears that TM expression may have different biological effects in different cell types. The physiological roles of TM expression in vascular SMCs and macrophages in atherosclerotic lesions remain to be elucidated.
Soluble TM fragments containing the EGF-like domain of native TM 6 are present in circulating plasma. 7 In the current study, we demonstrated that rTME1-6 concentrations of 1 nmol/L have a mitogenic effect on vascular SMCs. The plasma levels of soluble TM antigen are Ϸ0.1 nmol/L to 0.4 nmol/L in healthy adults but can exceed 1 nmol/L in patients with disorders such as diabetes mellitus, 41 disseminated intravascular coagulation, 42 and systemic lupus erythematosus. 43 To contribute to the proliferation of vascular SMCs, the soluble TM fragments in the circulating plasma must pass through the layer of endothelial cells lining the blood vessels. We hypothesize that the TM expressed by intimal SMCs and macrophages exerts its mitogenic activity on neighboring SMCs only after its release from dead cells. Alternatively, native TM on the cell surface may have a mitogenic activity comparable to that of the membrane-anchored heparin-binding EGF-like growth factor (pro HB-EGF), which exhibits mitogenic activity in vascular SMCs similar to mature HB-EGF. 44 HB-EGF, a member of the EGF family, is expressed in macrophages, endothelial cells, platelets, T cells, and vascular SMCs. Its expression is particularly high in atherosclerotic lesions compared with normal vessels. 45 Several other growth factors that are synthesized from membrane-anchored proteins are also biologically active in their transmembrane forms. For example, the precursor of transforming growth factor-␣ stimulates EGF receptor phosphorylation and mitogenesis. 46 This type of biological activity has been termed "juxtacrine stimulation." Consequently, membrane-anchored TM may act on intimal SMCs via a juxtacrine mechanism.
To investigate the correlation of TM expression with proliferation of SMCs, we performed double immunohistochemical staining of proliferating cell nuclear antigen (PCNA) and TM on atherosclerotic lesions under several conditions. Double immunofluorescent staining of the atheromatous plaques showed only TM-positive vascular SMCs. There was no distribution of PCNA-positive cells in the intima. A few PCNA-positive spindle cells, which are negative for TM, were found in the adventitia but not in the intima. It is well known that there are very few PCNA-positive cells within human atherosclerotic lesions. On the other hand, it has almost been established that intimal SMCs have mitogenic activity. We consider it very difficult to detect PCNA-positive SMCs immunohistochemically, mostly because of the rapid cell cycle of the SMCs, which makes detection of PCNA-positive cells difficult.
Chemotaxis of medial SMCs to the intima and proliferation of intimal SMCs are important in atherogenesis. 11 If TM shares biological functions with other members of the EGF family, it may contribute to SMC differentiation and chemotaxis. However, additional research on TM is required to elucidate its role in atherosclerosis.
